The synthesis of trans-5-amino-3-[2-(5-nitro-2-furyl)vinyl] _A2_1,2,4-oxadiazole (SQ 18,506) and its antimicrobial activity in vitro have been reported (1, 5, 6) . Preliminary chemotherapeutic experiments in which the drug was administered parenterally (Salmonella schottmuelleri) or orally (Trichomonas foetus) to infected mice suggested that meaningful efficacy in vivo was possible (5) . Extensive evaluation of SQ 18,506 in mice and in monkeys infected with Schistosoma mansoni (2) or S. japonicum (4) has shown the compound to possess significant chemotherapeutic activity with no apparent toxicity for the host. Direct ovicidal activity was also demonstrated. The present paper extends the evaluation of the compound to laboratory animals infected with a variety of other infectious agents and presents evidence indicating that the compound may be effective when administered topically for treatment of certain experimental vaginal infections.
MATERIALS AND METHODS
Antimicrobial agents. The antimicrobial agents used in this study were furazolidone, lot 1814 (Eaton Laboratories); nifuratel, batch 4 (Polichimica A.A.P.); metronidazole, lot 210 (Societe Parisienne D-Expansion Chimique SA); and SQ 18,506, batch 11, average particle size 3 to 5 jAm (Squibb).
Marketed products. The following topical preparations, purchased on the open market, were used in the study: 0.2% nitrofurazone (Furacin topical cream, Eaton Laboratories); .0.25% furazolidone and 0.375% nifuroxime (Trichofuron vaginal powder, Eaton Laborotories); 250 mg of nifuratel pessaries (Magmilor vaginal pessaries, Calmic Ltd.); 15% sulfanilamide and 0.2% aminacrine hydrochloride (AVC cream, MerrellNational Laboratories); 0.06% candicidin (Candeptin vaginal ointment, Julius Schmid, Inc.); 1% cholordantoin and 0.05% benzalkonium chloride (Sporostacin cream, Ortho Pharmaceuticals); and nystatin, 100,000 U/g (Mycostatin cream, Squibb). SQ 18,506 formulations. For parenteral treatment, SQ 18,506 was first solubilized in dimethyl sulfoxide and then diluted in distilled water to obtain the desired concentration. For oral treatment, the nitrofuran was suspended at the desired concentration in 5% gum acacia. Three different types of topical bases were used for the topical application of SQ 18,506: (i) cream base 1 (CB-1) containing cetyl alcohol, glyceryl monostearate, spermaceti, isopropyl palmitate, methyl and propyl parabens, and distilled water; (ii) cream base 3 (CB-3) containing promulgen, petrolatum, propylene glycol, and distilled water; and (iii) polyethylene glycol base (PEG) containing the polyethylene glycols 300 and 4,000. SQ 18,506 was formulated at the appropriate concentration (wt/wt) in these bases by blending the crystalline powder into each base. In some experiments other antimicrobial agents were formulated in the same vehicles as was SQ 18,506 so that comparative efficacies could be studied.
Antimicrobial activity in vitro. Minimal inhibitory concentrations were determined by the conventional twofold tube dilution method using broth media as previously described (9) . SQ 18,506 was solubilized in dimethyl sulfoxide and then diluted in water to obtain the concentrations required for testing.
Animals. Male or female white Swiss mice of the CF1-S strain (Carworth Farms, 18 to 20 g) were used in all acute infection experiments. For all vaginal infection experiments, guinea pigs of the Hartley strain (Harpaul Farms, 350 to 450 g) or rats of the CFE strain (Carworth Farms, 180 to 200 g) were used. Male guinea pigs (same strain and sources as listed above; weight range, 225 to 250 g) were used for all topical infection experiments. Mice were maintained 10 to a pan on bedding; guinea pigs and rats were individually caged on wire. Animals received food and water ad libitum.
Efficacy in experimental systemic infections. The procedures for producing the experimental T. foetus (8, 9) , Mycobacterium tuberculosis (11) , and Candida albicans (9) infections and evaluating test compounds in these infections have been described previously. Other experimental infections were produced by the intraperitoneal injection of suitably diluted cultures containing 1,000 (streptococci) or 100 (gram-negative bacteria) median lethal doses. Under these conditions, all untreated control mice died within 72 h. Mice infected with these organisms were given medication on the day of challenge and daily thereafter for a total of 3 days and observed for a total of 6 days.
In all experimental systemic infections, at least three different dosage levels of the test compound in fourfold increments were used; each dosage group consisted of 10 mice. The efficacy of SQ 18,506 and control drugs in the experimental infections was assessed on the basis of the median effective dose which protected 50% of the mice from the lethal effects of each infection. The median effective dose was determined by the method of Reed and Muench (12) .
Efficacy in experimental dermatophytosis. The methods used to produce this infection have been described earlier (10) . Briefly, the infection was produced on the flanks of guinea pigs by the intradermal inoculation of a spore suspension of Trichophyton mentagrophytes by means of a multiple-puncture device. The topical application of a test formulation on infected sites (0.5 g of formulation per site) began 3 days after infection and was continued once daily for 5 consecutive days each week for a total of 10 treatments. Concomitantly, triamcinolone acetonide (Squibb) was administered subcutaneously at a 30 mg/kg dosage level. The efficacy of a formulation was based on its ability to inhibit or modify the course of the infection.
Efficacy in experimental vaginal infections. A T.
foetus vaginal infection was established in guinea pigs by using published procedures (9) . Guinea pigs in estrus, induced by the subcutaneous injection of 5 mg of estradiol valerate, were infected on 2 consecutive days by the intravaginal inoculation of a 0.5-ml inoculum from a 48-h broth culture (STS medium; BBL) of T. foetus SC 9644. SQ 18,506 and control formulations were administered topically (0.5 ml of formulation per guinea pig) beginning 3 days after the final inoculation of T. foetus and were continued once daily for two cycles of 5 consecutive days, 2 days apart. The efficacy of each formulation was evaluated by culturing in STS medium 0.5 ml of vaginal washings from test guinea pigs 3 and 10 days after the final treatment and noting the presence or absence of the infecting organisms. Washings were obtained from each guinea pig by vaginal lavage with 1 ml of saline.
An Escherichia coli vaginal infection was established in ovariectomized rats pretreated 2 days before infection with 1.0 mg of progesterone and 0.1 mg of estradiol valerate administered subcutaneously in a 0.5-ml dose. Two days after the hormonal treatment, which produced changes in the vaginal mucosa favorable for the maintenance of the E. coli infection, rats were infected intravaginally on 2 successive days with approximately 108 organisms contained in 0.1 ml of an inoculum prepared from an overnight broth culture of E. coli SC 8294. Three days after infection, rats were divided randomly into groups of four or five animals. One group was used as the pretreatment control; vaginal washings obtained from these rats by lavage with 1 ml of saline were cultured by conventional diluting and plating techniques to determine the number of E. coli cells in the vaginas immediately before treatment had begun. All other groups except an untreated control group were treated intravaginally three times daily for 4 days with a 0.2-ml dose of the desired formulation (ground pessaries and powder were insufflated at the rate of 200 mg per dose). Eighteen hours after the final treatment, vaginal washings were collected from all rats and cultured to determine the number of organisms remaining. The efficacy of each formulation was then determined by magnitude of the reduction from the pretreatment count in rats treated with that formulation, relative to the number of organisms found in the vaginas of untreated rats.
The same animals and procedures used for the studies with E. coli described above were used to study the effect of SQ 18,506 on animals infected with Candida albicans with the following exceptions: rats were made diabetic by treatment with alloxan (14) before infection; hormonal pretreatment consisted of 0.5 mg of progesterone and 0. The efficacy of two SQ 18,506 formulations containing the drug at a 10% concentration was compared with selected commercially available products in the topical treatment of an experimental infection of the rat vagina caused by E. coli. Both formulations of SQ 18,506 were significantly more effective than any of the marketed products ( Table 3 ). The difference in activity between the two SQ 18,506 formulations was not significant. It should be noted that the PEG base alone was slightly active against the infection, producing slight improvement in 21% of the mice treated with the base. CB-3 was essentially inactive.
The comparison of the topical efficacy of the two SQ 18,506 formulations and selected marketed products in the experimental C. albicans vaginal infection in the rat is shown in Table 4 . In the therapy of this infection, the two SQ 18,506 formulations appeared to be as efficacious as the three most active marketed products: nystatin cream, candicidin vaginal ointment, and a sulfanilamide-aminacrine hydrochloride cream. It should be pointed out that some spontaneous improvement, based on the reduction in the pretreatment C. albicans vaginal count, occurred in untreated mice. Also, both bases used for formulating the SQ 18 administered subcutaneously or orally to mice infected with a variety of microorganisms. A favorable response was noted only in those infections in which the infecting organism was found to be extremely susceptible to SQ 18,506 in vitro, exhibiting minimal inhibitory concentration values of < 1.0 ,g/ml (Table 1) .
The results of this animal study give strong inferential evidence that the administered compound was either poorly absorbed or distributed, extensively metabolized in the animal body, or both. A study parallel to the present investigation has shown SQ 18,506 to be poorly absorbed after oral administration to a variety of animal species, including mice and rats (13) . In addition, extensive metabolism of the compound occurred when "4C-labeled SQ 18,506 was incubated with mouse-liver homogenate (7) . Hence, it may be concluded that any antimicrobial effects observed after oral or parenteral administration of the compound could be the result of the action of one or more of its metabolites. Further evaluation of SQ 18,506, with the exception of studies in mice infected with Trichomonas, was therefore limited to the topical administration of the drug in guinea pigs and rats.
Previous data demonstrated that SQ 18,506 was active in vitro against a number of microorganisms known to cause infections of the vagina in animals and humans (6) . Therefore, a study was undertaken to evaluate the compound in experimental vaginal infections due to organisms primarily responsible for these infections in humans: Candida albicans, Trichomonas vaginalis, and to a much lesser extent, bacterial species (3). Several antimicrobial agents, including nitrofurans, and various marketed products that are used clinically in the treatment of the various vaginal infections were included in the study for comparative purposes.
We found no significant difference between the activity of a drug against T. vaginalis and T.
foetus in vitro (unpublished data). Because experimental infections with T. vaginalis are extremely difficult to establish, an experimental T. foetus vaginal infection has normally been used in evaluating the antitrichomonal activity of test compounds. SQ 18,506 was found to be as active as nifuratel, furazolidone, and metronidazole when administered orally in the systemic T. foetus infection in the mouse or topically in the intravaginal infection in the guinea pig.
C. albicans and E. coli were used as test organisms representative of the mycotic and bacterial vaginal infections, respectively. For these infections the SQ 18,506 was formulated in two different topical bases, PEG and CB-3, at a 10% concentration, an approximation of the clinically proposed dosage of 200 mg of drug activity per day. Although both SQ 18,506 formulations were equally efficacious in the two infections, the activity of the two bases alone somewhat complicated the evaluation of the complete formulations. The PEG base exhibited slight activity against both the C. albicans and E. coli infections; CB-3 demonstrated slight activity only against the C. albicans infection. The activity of the PEG base was traced to residual ethylene oxide retained in the PEG from the production process. The activity of CB-3 can probably be attributed to the mixture of methyl and propyl parabens used as preservatives in many marketed topical preparations at the time of the study. However, in both cases, the complete SQ 18,507 formulations were more active than either base alone.
In both model infections, the responses of the infected rats to treatment with a specific agent appeared to be individualistic rather than all or none. Thus, not all rats in a particular group responded in the same manner, unless the formulation was either markedly efficacious or entirely devoid of activity. This result is analogous to the response of human patients under treatment for vaginitis. Although the variation in response of the treated rats somewhat complicates the evaluation of the test compounds, the response in this model nevertheless simulates the results obtained in clinical studies and, thus probably contributes to a more definitive preclinical assessment of the efficacy of a drug.
